| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
SVP, Finance, Chief Acct Officer | SVP, Finance, Chief Acct Officer
1 company
Joseph R Young is SVP, Finance, Chief Acct Officer at VERA. Joseph R Young's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $2.5M at current prices.
Our model assigns Joseph R Young a middling insider score of 61/100, based on 6 past trades. Over a 12-month horizon, 75.0% of those trades were profitable, with an average 12-month return of +20.3%.
The VERA filings lean toward selling, a net 48,954 shares.
Joseph R Young has 15 Form 4 filings on record from May 2021 to September 2026, all as SVP, Finance, Chief Acct Officer at Vera Therapeutics (VERA), 2021–2026.
The 25 reported transactions were 7 option exercises, 7 open-market sales, 6 option or other derivative awards and 4 stock awards, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 1 purchase worth about $40K and 4 sales worth about $2.1M.
The only open-market purchase was 5,714 shares of VERA at an average $7.00 on February 6, 2022, about $40K. Twelve months later VERA was down 66%.
The largest open-market sale was 30,837 shares of VERA at an average $42.30 on May 16, 2024, about $1.3M. Twelve months later VERA was down 49%.
None of the 4 sales since April 2023 was marked as made under a Rule 10b5-1 trading plan.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Feb 23, 2026 | VERA Vera Therapeutics, Inc. | SVP, Finance, Chief Acct Officer | Sell | 3,117 | $41.98 | $130,863.82 | -4.6% | -18.4% | - | |
| Nov 11, 2025 | VERA Vera Therapeutics, Inc. | SVP, Finance, Chief Acct Officer | Sale+OE | 15,000 | $29.06 | $435,874.50 | -23.9% | +47.6% | - | |
| May 16, 2024 | VERA Vera Therapeutics, Inc. | SVP, Finance, Chief Acct Officer | Sale+OE | 30,837 | $42.30 | $1,304,435.34 | -37.6% | -9.6% | -49.3% | |
| Apr 10, 2024 | VERA Vera Therapeutics, Inc. | SVP, Finance, Chief Acct Officer | Sell | 5,714 | $40.00 | $228,560.00 | -9.7% | -15.8% | -47.6% | |
| Feb 6, 2022 | VERA Vera Therapeutics, Inc. | SVP, Finance, Chief Acct Officer | Buy | 5,714 | $7.00 | $39,998.00 | +33.7% | -9.1% | -65.8% |